ACLARIS THERAPEUTICS INC reports a Return on Equity (ROE) of -48.49%.

What is ACRS's dividend yield?

ACLARIS THERAPEUTICS INC offers a dividend yield of 0.00%.

What is ACRS's Deepscope Quality Score?

Deepscope rates ACRS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ACRS?

Deepscope's AI Timing Score for ACRS is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ACRS belong to?

ACLARIS THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

ACRS (NASDAQ) Stock Analysis | ACLARIS THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-03 | FS: 2026-03-31)

ACRS

ACLARIS THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 4.42

-0.21 (-4.54%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-48.5%

ROE

-35.1%

ROA

0.00%

Div Yield

ACLARIS THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.42 Price -0.21 (-4.54%) Day Change	NEWS SCORE: 87

ACRS, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.42
PBV / Sector	4.50 / 4.48
Earning Per Share	-0.48

PE / Sector	N/A / 16.68
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	5.87 M GREAT
Average 1W Daily Value	6.39 M

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-832.58 / 450.37
NPM Average (%) / Sector	-588.58 / -1,506.30
NPM Change Average (%) / Sector	41.01 / 4,941.44 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-35.06 / 30.83
ROA Average (%) / Sector	-42.88 / -347.12
ROA Change Average (%) / Sector	4.79 / 5,126.35
ROE (%) / Sector	-48.49 / -3.04
ROE Average (%) / Sector	-59.33 / 40.76
ROE Change Average (%) / Sector	7.50 / 2,110.63
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 5.25

Registration Details

Analyze Date	2026-06-04 09:23:57
Symbol	ACRS
Name	ACLARIS THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	139.66 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	646.64 / 8,483.11

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 701 Lee Road, Wayne, PA, United States, 19087

Phone: 484 324 7933

Website: https://www.aclaristx.com

Employees: 69

Sector: Healthcare >> Biotechnology

Description: Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.